NASDAQ:FTSV Forty Seven (FTSV) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free FTSV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$95.51▼$95.5150-Day Range$95.51▼$95.5152-Week Range$5.53▼$95.51VolumeN/AAverage Volume1.61 million shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Forty Seven alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Forty Seven Stock (NASDAQ:FTSV)Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. FTSV Stock News HeadlinesMay 2, 2024 | msn.com95.7 The Game hosts warn 49ers' first-round pick not to say 'San Fran'April 28, 2024 | msn.comUSS Forrestal: Triumph and Tragedy of America's First 'Super' Aircraft CarrierMay 6, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 27, 2024 | ninerswire.usatoday.comNFL Twitter reacts to 49ers drafting Florida State CB Renardo Green in second roundApril 9, 2024 | msn.com49ers sign veteran tight endMarch 28, 2024 | msn.comParent Of FTX Victim Who Lost $130K Recommends Six-Year Sentence For Sam Bankman-Fried, Countering DOJ's 40-50 YearsNovember 16, 2023 | morningstar.comFormula Systems (1985) Ltd ADR FORTYOctober 27, 2023 | nypost.comSix young men found dead, one injured in search for seven abducted Mexican teenagersMay 6, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.October 10, 2023 | bizjournals.com$18M upgrade makes historic downtown Milwaukee high-rise a modern data centerSeptember 11, 2023 | msn.comTampa radio station 101.5 has changed from Top 40 to R&B formatAugust 18, 2023 | msn.comJRA Chair: Seven businesses coming to Farish StreetJune 11, 2023 | dailymail.co.ukWeek one: seven-day detoxApril 18, 2023 | dailymail.co.ukI'm a fitness coach. These are the seven exercises that are a complete waste of your timeMarch 22, 2023 | thetimes.co.ukForty racists beat me with sticks in the name of a conspiracy theoryJanuary 2, 2023 | finance.yahoo.comForty-Five Percent of Public Schools Operating Without a Full Teaching Staff in October, New NCES Data ShowOctober 1, 2022 | bizjournals.comMeet our Forty Under 40 winnersJune 18, 2022 | news.yahoo.comSouth wins 51st Ken Lantzy Finest 40 All-Star Classic in shootoutMay 27, 2022 | investing.comFTSV_old Historical DataSee More Headlines Receive FTSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today5/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FTSV CUSIPN/A CIKN/A Webwww.fortyseveninc.com Phone650-352-4150FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.38% Return on Assets-44.35% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$15.68 million Price / Sales293.33 Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book12.70Miscellaneous Outstanding Shares48,156,000Free FloatN/AMarket Cap$4.60 billion OptionableNot Optionable Beta0.40 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Mark A. McCamish (Age 66)Pres, CEO & Director Dr. Craig S. Gibbs (Age 56)Chief Bus. Officer Dr. Chris H. Takimoto M.D. (Age 60)Ph.D., Chief Medical Officer Mr. Mark ChaoFounder & VP of Clinical Devel.Mr. Jens-Peter VolkmerFounder and VP of Research & Early Devel.Key CompetitorsPerrigoNYSE:PRGONuvalentNASDAQ:NUVLOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIOAlpine Immune SciencesNASDAQ:ALPNView All Competitors FTSV Stock Analysis - Frequently Asked Questions How were Forty Seven's earnings last quarter? Forty Seven Inc (NASDAQ:FTSV) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) EPS for the quarter, hitting analysts' consensus estimates of ($0.38). The company earned $15.68 million during the quarter, compared to the consensus estimate of $15.80 million. What other stocks do shareholders of Forty Seven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer (ET), TG Therapeutics (TGTX), Gilead Sciences (gild), Unisys (UIS), Inovio Pharmaceuticals (INO), GlycoMimetics (GLYC), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT). When did Forty Seven IPO? Forty Seven (FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers. This page (NASDAQ:FTSV) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDollar CancelledLear CapitalElon to Transform U.S. Economy? Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forty Seven Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
